Injectable POLY-L-Lactic Acid for Treatment of Hill and Valley Acne Scarring

Inclusion Criteria: * Outpatient seeking therapy for correction of hill and valley acne scarring. * Ability and willingness to understand and comply with requirements of the trial Exclusion Criteria: * The subject has active acne or chronic skin disease, inflammation or related conditions, such as infection, psoriasis and herpes zoster * History of presence of keloid formation or hypertrophic scars * History of procedures that precipitate an active dermal inflammatory or hyperplastic response (i.e., epilation or radiofrequency laser and chemical peeling procedures) within one month of study entry * History of use of facial tissue augmenting therapy or aesthetic facial surgical therapy within six months prior to study entry * Concomitant anticoagulant therapy, antiplatelet therapy or has any bleeding disorders * History of unanticipated adverse reactions when treated with hyaluronic acid based products * Any condition which in the opinion of the investigator makes the patient unable to complete the study per protocol (e.g., patients not likely to avoid other facial cosmetic treatments; patients not likely to stay in the study for its duration because of other commitments, concomitant conditions, or past history; patients anticipated to be unreliable, or patients who have a concomitant condition that may develop symptoms that might confuse or confound study treatments or assessments) * History of or current cancerous or pre-cancerous lesions in the area to be treated * Use of any investigational drugs or any other medical devices within 30 days of enrolment * Use of any prohibited medication within a proscribed time period before entry * Pregnancy * Recent use of Accutane (patient should not be on Accutane for the last 6 months) * History of allergic/anaphylactic reactions, including hypersensitivity to local anaesthetics (lidocaine) * Recent history of trauma in the face (less that 1 year) * Previous of Dermalive or Dermadeep The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.